A recurrent t(12;21)(p13;q22) has recently been described in human acute lymphoblastic leukemias (ALLs). This translocation fuses E L and AML7, two genes previously cloned from translocation breakpoints in myeloid leukemias. In addition, allelic loss of the TEL gene can be detected in 1590 t o 22% of childhood ALLs. In the present study, we have sought allelic deletions of TEL and the presence of the t(12;21) in 50 children with B-lineage ALL, using a combination of microsatellite typing, fluorescent in situ hybridization (FISH), and analysis of the fusion transcripts resulting from the TEL-AML7 gene fusion. Our results indicate that the association between the t(12;21) and the deletion of the nontranslocated allele of E L is among the most frequent abnormalities observed in B-lineage ALLs. FISH analysis using several cosmid probes showed that, in one patient with a t(12;21) translocation involving TEL, the second allele had YTOGENETIC ALTERATIONS of the short arm of chromosome 12 (12p) are detected in about 10% of childhood acute lymphoblastic leukemia (ALLs).' These abnormalities consist of both translocations and deletions.' The translocations can be either balanced or unbalanced and involve several partner chromosomes. Interstitial or terminal deletions account for up to 50% of 12p alterations and are occasionally associated with translocations.'
A recurrent t(12;21)(p13;q22) has recently been described in human acute lymphoblastic leukemias (ALLs). This translocation fuses E L and AML7, two genes previously cloned from translocation breakpoints in myeloid leukemias. In addition, allelic loss of the TEL gene can be detected in 1590 t o 22% of childhood ALLs. In the present study, we have sought allelic deletions of TEL and the presence of the t(12;21) in 50 children with B-lineage ALL, using a combination of microsatellite typing, fluorescent in situ hybridization (FISH), and analysis of the fusion transcripts resulting from the TEL-AML7 gene fusion. Our results indicate that the association between the t(12;21) and the deletion of the nontranslocated allele of E L is among the most frequent abnormalities observed in B-lineage ALLs. FISH analysis using several cosmid probes showed that, in one patient with a t(12;21) translocation involving TEL, the second allele had YTOGENETIC ALTERATIONS of the short arm of chromosome 12 (12p) are detected in about 10% of childhood acute lymphoblastic leukemia (ALLs).' These abnormalities consist of both translocations and deletions.' The translocations can be either balanced or unbalanced and involve several partner chromosomes. Interstitial or terminal deletions account for up to 50% of 12p alterations and are occasionally associated with translocations. ' Detection of loss of heterozygosity (LOH) in tumor cells can reveal microdeletions that usually remain undetected by cytogenetic analyses. Recently published indicate that alterations of the 12~312-13 region are largely underestimated by standard cytogenetics. In both studies, microsatellite markers located in this chromosomal region were typed on matched pairs of diagnostic and remission samples from children with ALL. The maximum rate of LOH was found at the D12S89 locus. Allelic loss of this marker was detected in 15% to 22% of the informative patients? and reached 27% when ALLs of the B-lineage were analyzed ~eparately.~ Such a high frequency of deletions suggests that this region contains a tumor suppressor gene whose inactivation may account for tumor initiation and/or progression. KIP I, the gene encoding the cyclin-dependent kinase p27 has been proposed as a possible target of the deletions3 However, we recently described one patient where this gene was located outside of the deleted region: and sequencing of the remaining alleles in 10 patients with monoallelic deletions of KIP I did not reveal the presence of any mutation: in agreement with other report^.^,^ Another candidate gene is TEL This gene encodes an ETS-related putative transcription factor that was first identified by cloning the t(5; 12)(q33;p13) breakpoint in a chronic myelomonocytic leukemia (CMML).' TEL is located in the deleted region common to many ~atients.'".~ In addition, a recurrent t(12;21)(p13;q22) has been described in several human ALLs: and two groups have reported that this translocation fuses the TEL gene to AMLI,"'." a gene previously cloned from translocation breakpoints in acute myeloid leukemias (AML).I2 Interestingly,
C
Blood, Vol 87, No 7 (April l ) , 1996: pp 2891-2899 an intragenic deletion. This observation points t o TEL as the actual target of 12~12-13 deletions in patients that associate a t(12;21) with a deletion. The TEL-AML7 fusion RNA was found in all patients with the t(12;21) whereas the reciprocal AML7-TEL transcript was only found in a subset of patients, suggesting that only the protein product encoded by TEL-AML7 is likely t o play a role in leukemogenesis. The observation that, in t w o patients with the t(12;21), a deletion of TEL was only present in a subclone indicates that this deletion was a secondary event that occurred after the translocation. The frequent occurrence of TEL deletions in patients with t(12;21) suggests that the deletion of the normal E L allele subsequent to the t(12;21) provides a further proliferative advantage t o leukemic cells. all four patients reported with the TEL-AMLZ gene fusion also had a deletion of the nontranslocated allele of TEL.'"~"
To determine what extent deletions involving the 12~12-13 chromosomal region were associated with translocations of the TEL gene, we investigated a series of children with B-lineage ALL. These patients were studied for allelic deletion of TEL and for the presence of the t( 12; 21 ), using a combination of LOH study, fluorescent in situ hybridization (FISH) mapping, and reverse transcription-polymerase chain reaction (RT-PCR) analysis of the fusion transcripts resulting from the TEL-AMLI gene fusion.
MATERIALS AND METHODS
Patients. We studied 66 children (from 3 days to 15 years old) with B-lineage ALL. The diagnosis of B-precursor ALL was based 2892 RAYNAUD ET AL on the expression of B-cell-associated antigens (CD19, CD22, CDIO) and the lack of surface membrane Igs.
Surnple collection and preparation of mononuclear cells. Bone marrow (BM) was collected on EDTA before induction therapy and during clinical remission, between 6 and 24 months of therapy according to the EORTC S8 88 I follow-up protocol, Informed consent was obtained from the patients, their parents, or both, as appropriate. At the time of diagnosis, all BM samples contained more than 70% blasts. Mononuclear cells were separated by gradient centrifugation over Ficoll (Lymphoprep; Pharmacia, Uppsala, Sweden), washed in 0.9% NaCI, counted, and aliquots of cells were stored at -80°C until used.
Cyrogenetic studies. Cytogenetic studies were systematically performed at presentation on BM cells. Metaphases were obtained from short-term unstimulated cultures (24 and 48 hours). Chromosomes were identified using RHG and/or trypsin-Giemsa banding techniques and classified according to the International System for Cytogenetic Human Nomenclature.'' Probes. 9S8b8 is a 1.2 Mb yeast artificial chromosome containing the TEL gene obtained from the Centre d'Etude du Polymorphisme Humain (CEPH, Paris, France).
The cosmid probe cos 179A6 was isolated from the Lawrence Livermore library LL12NC01I4 by hybridization with an oligonucleotide probe (TGAGACATGTCTGAGACTCCTGCT) derived from the TEL cDNA sequence.' The isolation of cosmid probes cos S0F4, cos 163E7, and cos 148B6 has been reported previously."
Cycle sequencing was performed using fluorescein-labeled oligonucleotides derived from the TEL cDNA sequence' and the dsCycle Sequencing kit (GIBCO-BKL, Gaithersburg, MD). The reaction products were separated on an automated laser fluorescence (ALF) sequencer (Pharmacia).
Direct visualization by i n situ hybridization (DIRVISH) on stretched DNA fibers with digoxigenin-labeled and biotin-labeled probes was performed as described previously.I6 We also used a centromere-specific probe for chromosome 12 (GIBCO-BRL) and a whole chromosome painting probe for chromosome 21 (coatasome. Oncor; Dako, Trappes, France).
FISH unulysis. FISH was performed as previously described."
Biotin-labeled probes were prepared using a Bio-Nick Kit (GIBCO-BRL). The signal was detected using fluorescein isothiocyanate (FITC)-conjugated avidin (Vector Laboratories, Biosys, Compikgne, France). Slides were examined using a DAPI/FITC/rhodamine tripleband pass filter set (Chromatechnology, Zeiss. Marseille, France). Fluorescence images were captured with a high resolution cooled charge-coupled device color camera (PSI, Chester, UK) with optimized sensitivity in fluorescent light. Image enhancement and analyses were done using a ProbeMaster FISH workstation (PSI). Optimal hybridization conditions were set up by hybridizing all biotin-labeled probes to metaphase cells prepared from mitogen-stimulated lymphocytes. The presence or absence of the FISH signals was scored on an average of 15 abnormal metaphase cells (2 to 35 cells) per probe per patient.
DNA anulysis. Microsatellite markers D12S77, D12S89, D12S358 located in the chromosomal region 12~12-13 were typed as previously described.4 Primer sequences and percentage of heterozygosity were obtained from the Genome Data Base (Welch Medical Library, Johns Hopkins University, Baltimore, MD). The presence of the polymorphic marker D12S89 was tested on individual cosmids by PCR.
RT-PCR analysis. RNA was extracted from blasts and RT was performed from 1 l g of RNA using random priming as previously described.'" One tenth of the reaction was submitted to PCR amplification with various combinations of primers: TEL-AMLI was amplified using PTEL (TCCCCGCCTGAAGAGCACGCC; nucleotides 991-101 l)' and NAMLI (AGCGGCAACGCCTCGCTCAT; complementary to nucleotides 751-770)." AMLI-TEL was amplified using PG4 (GGAGGAAGCGATGGCTTCAGACAGC; nucleotides 172-196 of G4 sequence)" and NTEL (CCACAGTCGAGCCAG-TCCGTTGG, complementary to nucleotides 1142-1 la).' The quality of the cDNAs was checked by amplifying TEL cDNA using PTEL and NTEL, and AMLI using PG4 and NAMLI.
PCR were performed in 25-pL reaction mixtures containing I O mmol/L TRIS-HCI (pH 9.0), SO mmoVL KCI, 2.5 mmol/L MgCl,, 200 pnol/L of each dNTP, I O pmols of each primer, and 0.25 U of Taq polymerase (Appligene, Strasbourg, France). After a S-minute denaturation step at 94"C, 40 cycles were performed as follows: 10-second denaturation at 94°C 10-second annealing-extension at 57°C. Amplification was controlled by electrophoresis in 2% agarose and ethidium bromide staining.
Specificity of the amplification was tested by Southern blot hybridization to junctional probes for TEL-AMLI (TTCATGAGA-GACTGTAGACTG)" and AMLI-TEL (AGAATAGCAGAATGC-ATACT)." Specific oligonucleotides were 5' end-labeled with 32P using T4 polynucleotide kinase (Amersham, les Ulis, France). Probes were separated from unincorporated radioisotope by chromatography through Sephadex 2.5 (Pharmacia). Filter-bound DNAs were prehybridized for 1 hour at 50°C in 6X stock saline citrate ( I X SSC is 150 mmol/L NaC1. 1 S rnmoln sodium citrate), 0.5% sodium dodecyl sulfate (SDS). and SX Denhart's solution. Hybridization was cow ducted overnight in the same solution containing the radio-labeled probe ( 3 nmol/L) at 53°C. Filters were washed twice in 2 x SSC, I o/r SIX. A final stringent wash was performed in 0.2X SSC preheated at 50°C. Autoradiographic detection was performed using XAR-S film (Eastman Kodak, Rochester, NY) exposed to the filters for 3 to 16 hours.
RESULTS
A series of 66 unselected children with B-lineage ALL was studied for LOH in the chromosomal region 1 2~1 2 -13. From this group, material was available for FISH in 35 cases and for RNA analysis in 27 cases. A total of 50 patients were studied for the presence of the t(12;21) by either FISH or RT-PCR. Clinical features of these 50 patients are summarized in Table 1. Allelic loss cf TEL i n B-lineage ALLs. Microsatellite markers were amplified by PCR and results obtained with samples prepared from blasts were compared to matched samples obtained at complete remission from the same patients. Allelic loss in blast cells was usually detected as a drastic decrease in the signal corresponding to one allele rather than its complete disappearance because of the presence of some normal cells in the diagnostic samples. From the initial series of 66 patients, we observed 16 patients with allelic loss of the TEL gene as detected by either LOH of D12S89 (14 of 61 informative patients) or LOH of the flanking markers D12S77 and D12S358. A summary of LOH data is presented in Table 2 . A detailed analysis of the extent of deletions has recently been reported for the first I 1 patients."
Cytogenetics. Cytogenetic analysis was performed at the time of primary diagnosis for all 50 patients and good quality metaphases were obtained for 48 of them. Clonal abnormalities were identified in 30 patients, and did not differ from those usually reported in ALLs. For the 32 patients who did not carry 12p molecular rearrangement, these abnormalities * Two der(21) with a positive signal were observed.
17, the fraction of metaphase cells with a signal on chromosome 12 is indicated.
togenetic analysis. Four patients had a deletion of chromosome 12p that was present either in all metaphases from the malignant clone (cases 5 and 16) or in a fraction of abnormal metaphases (cases 12 and 15). Translocations of 12p arm were detected in 6 cases, and involved 6 other chromosomes (namely chromosomes 1, 3, 6, 8, 13, and 15). Characterization of the cosmid probes used for FISH. Several exons of the TEL gene were mapped to the previously isolated cosmids cos5OF4, cos163E7, and c0s148B6'~ by hybridization of Southern blots with cDNA probes and partial sequencing of the cosmids (Peter Marynen, unpublished data, July 1995). The approximate positions of the exons are indicated on a partial genomic map of TEL (Fig l) . To isolate the 5' end of the TEL gene, the LL12NCO1 library was screened with an oligonucleotide probe corresponding to nucleotides 19-42 of the TEL cDNA. Cos179A6 was isolated and shown by sequencing to contain a TEL exon ending at nucleotide 57 of the TEL cDNA' with a proper consensus 5' splice donor sequence. This cosmid thus carries the 5' end of the published coding sequence of TEL. All cosmids were then screened for the presence of markers derived from the region around the TEL locus. The polymorphic (CA)n repeat D12S89 was localized by PCR and hybridization to a 5.4-kb EcoRI fragment of cos5OF4 immediately 5' to a 3.1-kb fragment containing TEL exon 2 (Fig 1) . FISH analysis. FISH was first performed using YAC 958b8 and/or cos5OF4 probes. The FISH results for patients with 12p abnormalities are summarized in Table 2 . Among the 35 patients with cells available for FISH analysis, we detected a t(12;21) in 11 cases. All but 2 of these patients (cases 12 and 17) had allelic loss of TEL detected by LOH studies (Table 2 ). In 9 patients, a positive signal was observed on both the der(l2) and the der(21) chromosomes using the YAC 958b8 probe (Fig 2a) or on the der(21) chromosome alone after hybridization with cos5OF4 (Fig 2b) , but not on the cytogenetically normal chromosome 12 using either one of these 2 probes. These results show the existence of an interstitial deletion of the nontransiocated chromosome 12 that was not detected by conventional cytogenetics. The same result, a single signal on the der(21) chromosome, was observed with cos5OF4 in a fraction of the cells from 2 other patients (cases 12 and 17), although most of the cells yielded an additional signal on the nontranslocated chromosome 12 Patients' numbers are the same as in Tables 1 and 2 . Karyotypes from patients 1 through 12 have previously been reported.' (Table 2) . We concluded that, in these 2 patients, a nonrandom deletion involving TEL was present in a minor subclone. Results from LOH studies pointed out that patient 8 displayed a LOH of a single marker (D12S89) suggesting that the deletion had a much smaller size than those found in other patients. Therefore we performed additional FISH experiments in this patient to better characterize the extent of the deletion. Cos179A6 and cos163E7 yielded positive signals on the der(21) chromosome and on the cytogenetically normal chromosome 12 of this patient (Fig 2c and d , respectively), whereas cos5OF4 (Fig 2B) hybridized to the der(21) chromosome only. Cos148B6 gave a positive signal on both chromosomes 12 (Fig 2E) . The presence of a t(12;21) in these metaphase cells was confirmed by chromosome painting using a chromosome 21 specific probe (data not shown). The constant presence of hybridization signals on the nontranslocated chromosome 12 with all cosmid probes but cos5OF4 indicated the existence of an intragenic deletion of TEL. The observation that cos163E7 hybridized to the der(21) chromosome whereas cos148B6 hybridized to the der(l2) chromosome (Fig 2d and e) showed that the 1 2~1 3 breakpoint of the t( 12; 21) was located between cos163E7 and cos148B6, in agreement with the localization of these cosmids with respect to the position of the breakpoint in the TEL cDNA (Fig 1) .
FISH performed in case 13, using cos5OF4 and YAC 958b8, revealed a positive signal on two der(21) chromosomes in all cells analyzed (data not shown). These data suggested that the trisomy 21 observed by conventional cytogenetics in this patient (Table 3 ) was a secondary event resulting from a duplication of the der(21) chromosome.
Patients 12 and 18, who had cytogenetic translocations involving chromosome 12 (Table 3) , were further explored. Chromosome painting using a chromosome 21 specific probe was performed; hybridization signals were observed on the der(6)t(6; 12) and the der(3)t(3; 12) chromosomes, respectively (data not shown), implying that these chromosome derivatives were also involved in the t(12;21). The mechanism involved in this three-way translocation was as follows:
the distal short arm of chromosome 12 was translocated to chromosome 21, whereas the end of chromosome 21 was translocated to the third chromosome involved and the remainder of the third chromosome was translocated to chromosome 12. Simultaneous hybridization with cos 50F4 and a chromosome 12 centromeric probe was performed on metaphase cells from patient 12; as expected a positive signal was observed for the cosmid probe on the der(21) chromosome and on the normal chromosome 12 but not on the der(12)t(6; 12) chromosome (Fig 2f) .
RNA analysis. Fusion transcripts specific for the t(12;21) were sought by RT-PCR in 27 patients for whom RNA was available. Among the 11 patients with a t(12;21) showed by FISH, 7 patients were studied by RT-PCR and a TEL-AML1 fusion RNA was detected in all of them. The same chimeric mRNA was also found in 5 additional patients who displayed an allelic loss of TEL but for whom no cells were available for FISH analysis. In all these cases, an amplified fragment of the expected length was obtained (Fig 3) .
By contrast, in 15 other patients with neither a documented t( 12; 21) nor an allelic loss of TEL, no TEL-AMLl fusion mRNA was ever detected (Table 1) . Among 12 patients for whom a TEL-AMLI fusion transcript was observed, 5 patients had no detectable reciprocal AMLl-TEL mRNA ( Table 1) .
DISCUSSION
Recent reports have indicated that LOH of microsatellite markers can be detected in 15% to 22% of childhood ALLs at chromosomal band 12~32.3 in a region containing TEL.. ' . ' The present study shows that 15 of 16 patients with allelic loss of TEL had a t( 12;21) detected by FISH and/or TELAMLl chimeric transcripts as shown by RT-PCR (Table l) . Only one patient with allelic loss of TEL had no demonstrable t(12;21) (case l ) . Conversely, 14 of 16 patients with a t( 12;21) had lost the nontranslocated allele of TEL (Table  l) . RT-PCR using a primer pair spanning the TEL-AMLI junction of the chimeric mRNA produced an amplified fragment of identical size in all patients examined, implying that the translocation breakpoint lies in the same introns of the TEL and AMLl genes in all patients studied.
Our results indicate that the association between the t( 12;21) and the deletion of the nontranslocated allele of TEL is among the most frequent abnormalities observed in B-lineage ALLs. This association has already been reported in 4 patients with childhood ALL."." By contrast, deletions of the chromosomal region 12pI 3 have been observed in some ALLs and in other hematopoietic malignancies that resulted either from unbalanced translocations of chromosome 12 or from interstitial deletions in the absence of t( 12;21).* Whether or not the target of the deletions is common to all cases remains unknown. Interestingly, in the 2 patients with t(12;21) for whom allelic loss of TEL was not initially detected by LOH studies (patients 12 and 17, Table   l ), FISH analysis revealed a deletion of the normal allele of TEL in a significant number of metaphases that displayed the t( 12;21). In patient 12, the absence of a signal on chromosome 12 in a subset of blasts corresponded to a terminal deletion of chromosome 12p detected by classical cytogenetics (Table 3 ). These findings suggest that the deletion is a secondary event that occurs with a high frequency in patients with the TEL-AMLI hybrid gene.
The prognostic significance of TEL alterations in ALLs should be evaluated. In our series, 3 of 18 patients with allelic loss of TEL and/or a t(12;21) relapsed as compared to IO out of 32 patients without molecular abnormalities of TEL. The small number of cases studied precludes any definitive conclusion, and the study of larger series is re- Table 2 ). In 2 patients (cases 12 and 1 8), results of chromosomal painting indicated that the t(6; 12) and the t(3; 12) translocations observed in these patients were complex variants involving chromosome 21. Interestingly, 4 out of these 6 patients had no AMLI-TEL fusion transcript whereas TEL-AMLI mRNA was detected ( Table I) . It may be hypothesized that, in these cases, sequences from either TEL or AMLl had been deleted resulting in the inactivation of the AMLI-TEL hybrid gene. Initial studies of the t( 12;21) have shown that both derivative chromosomes are transcriptionally active.'".'' However, our present data indicate that only the TEL-AMLI fusion RNA is found in all patients with the t( 12;21), whereas the reciprocal AMLI-TEL transcript is only detected in a subset of patients. These observations strongly suggest that only the protein product encoded by TEL-AMLI is likely to play a role in leukemogenesis.
Translocations involving TEL result in a modular combination of functional domains from TEL and from its various partners that are linked together as a result of the translocations. In a subgroup of patients with CMML, a t(5; 12) leads to the formation of a chimeric gene encoding a hybrid protein in which the helix-loop-helix (HLH) domain of TEL is linked to the platelet derived growth factor receptor beta (PDGFRP) and the TEL-PDGFRP fusion protein is thought to dimerize through the HLH domain of TEL. thus resulting in the activation of the tyrosine kinase domain of the PDGFRP.' In one case of pediatric ALL, amino-terminal sequences of TEL were fused to and activated the tyrosine kinase domain of the ABL protein,"' as a consequence of a t(9; 12) translocation. The t( 12;22) that is observed in some myeloid malignancies" fuses TEL to the MNI gene, a recently discovered gene of unknown function thought to encode a transcription factor."
org From
In the t( 12; 211, the putative TEL-AMLl hybrid protein possesses the HLH domain situated in the amino-terminal region of TEL fused to the entire AMLl protein.'"." The HLH domain may promote homodimerization of the TEL-AML 1 protein or heterodimerization with other HLH nuclear proteins, and thus modify the network of transcriptional regulation. A high level of expression of the hybrid protein that contains the functional domains of AMLl under the transcriptional control of the TEL promoter may also be involved in oncogenic transformation. We4 and others3 have previously reported that most patients with allelic loss of TEL have large deletions. One exception was previously identified4 and further studied in the present work (case 8). FISH analysis using several cosmid probes showed that this patient had a t( 12;21) translocation, and an intragenic deletion of the second allele of TEL. Although we did not exclude the possibility that another gene may be present within the TEL gene and inactivated by the deletion, this observation strongly suggests that TEL is the actual target of 12~12-13 deletions in patients that associate a t( 12;21) with a deletion. The association of a deletion with a translocation of TEL results in the inactivation of both alleles of this gene. This "loss of function" of TEL is consistent with the possibility that TEL is a tumor suppressor gene. In this case, one would expect to find other inactivating mechanisms such as homozygous deletions, as it is commonly found for the MTSI gene in ALLs." However, homozygous deletions of TEL have not been observed. Some:3 but not other translocations of TEL that also result in the functional inactivation of one allele are associated with the inactivation of the second allele. In the t(12;21), at least two hypotheses may account for the frequent occurrence of a deletion of the nontranslocated allele of TEL. On one hand, if TEL encodes a negative regulator of cell proliferation, the TEL-AMLI protein might partially inactivate the normal TEL protein through HLH-mediated dimerization. On the other hand, if the TEL-AML1 protein has by itself oncogenic properties, the normal TEL protein may exert a dampening effect by interacting with the hybrid protein as previously suggested." These hypotheses are not mutually exclusive, and, in either case, deletion of the normal TEL allele would provide a further proliferative advantage to leukemic cells with a t( 12; 21).
